The role of positron emission tomography in the management of non–small cell lung cancer

摘要: Despite many advances in the diagnosis, staging and treatment of non–small cell lung cancer (NSCLC), overall 5-year survival rate patients with resectable NSCLC is less than 50%.1 This suboptimal likely due to factors, including aggressiveness specific phenotype, locally advanced disease at presentation inaccurate pretreatment staging. It plausible that undetected locoregional distant micrometastatic time results or times inappropriate and, therefore, decreased stage-specific survival. Accurate clinical diagnosis has important advantages, which following 3 have particular importance it allows for appropriate patient selection potentially curative surgical and/or nonsurgical therapies, it identifies who would benefit from neoadjuvant therapy, and it more accurate follow-up assessment detection loco-regional recurrences might still be amenable salvage treatment. In management NSCLC, 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) an imaging technology evolving potential. The advantage FDG-PET lies its ability detect metabolic changes cells even before manifestation anatomic commonly identified by conventional modalities such as computed (CT), ultrasonography, magnetic resonance (MRI) bone scintigraphy. may help possible imaging. also identify tumours earlier stage, assess their response therapy surveillance. potential capability PET assessing tumour responsiveness chemotherapy can used a prognostic factor, thereby influencing direction further management. The optimal use continues evolve. poor prognosis lack stages facilitated rapid integration this NSCLC. However, financial burden on health care systems individual payers brought widespread into question. purpose review discuss current practical applications summarizing clinically applicable data. A systematic role already been published one us (Y.U.).2